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Objective: To identify the impact of delivery device of inhaled corticosteroids and long-acting 
β
2
-agonist (ICS/LABA) on asthma medication compliance, and investigate other factors associ-
ated with compliance.
Materials and methods: We conducted a retrospective and multicenter study based on a review 
of medical registries of asthmatic patients treated with ICS/LABA combinations (n=2,213) whose 
medical devices were either dry powder inhalers (DPIs, such as Accuhaler®, Turbuhaler®, and 
NEXThaler®) or pressurized metered-dose inhalers (pMDI). Medication compliance included 
persistence outcomes through 18 months and medication possession ratios. Data on potential 
confounders of treatment compliance such as asthma exacerbations, comorbidities, demographic 
characteristics, and health care resource utilization were also explored.
Results: The probability of asthma medication compliance in case of DPIs was lower compared 
to pMDIs, which suggests that inhaler devices influence inhalation therapies. There were 
additional confounding factors that were considered as explanatory variables of compliance. 
A worse measure of airflow obstruction (forced expiration volume in 1 second), comorbidities 
and general practitioner (GP) consultations more than once per month decreased the probability 
of compliance. Within comorbidities, alcoholism was positively associated with compliance. 
Patients of 29–39, 40–50, and 51–61 age groups or suffering from more than two exacerbations 
during the study period were more likely to comply with their medication regime. The effects of 
DPIs toward compliance varied with the different DPIs. For instance, Accuhaler® had a greater 
negative effect on compliance compared to Turbuhaler® and Nexthaler® in cases of patients who 
suffered exacerbations. We found that GP consultations reduced the probability of medication 
compliance for patients treated with formoterol/budesonide combination. For retired patients, 
visiting the GP increased the probability of medication compliance.
Conclusion: We concluded that inhaler devices influence patients’ compliance for long-term 
asthma medication. The impact of Accuhaler®, Turbuhaler®, and NEXThaler® on medication 
compliance was negative. We also identified some confounders of medication compliance such 
as patient’s age, severity of asthma, comorbidities, and health care costs.
Keywords: adherence, inhaler devices, medication possession ratio, dry powder inhalers, pres-
surized metered-dose inhalers, persistence
Introduction
Asthma is characterized by the inflammation of respiratory airway, hypersensitivity of 
airway path, and the variable airflow limitation during short periods of time. A controller 
medication is daily medication that is used to prevent or improve asthma symptoms 
in patients who experience them frequently. The medical decision to use a controller 
medication for a patient with asthma is based on the frequency and type of daytime or 
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nighttime symptoms, frequency of medical visits for asthma, 
frequency of requiring asthma rescue medications, frequency 
of oral steroid use, impact of asthma symptoms on daily life, 
and breathing tests for asthma. Inhalation therapy presents 
advantages in respect to oral or parenteral treatment such as 
easy access of the medication to the bronchoalveolar system 
and lower dosage.1 However, these attributes are diminished 
due to a poor compliance associated with deficient inhaler 
technique.2–5 Although inhaled corticosteroids and long-
acting β
2
-agonist (ICS/LABA) fixed-dose combinations 
have shown to relieve asthma symptoms, similarly,6,7 there is 
increasing research that claims that inhaler technique might 
affect compliance and hence, efficacy of pharmacological 
treatment.8,9
Several studies reported a critical problem of patients’ 
compliance in chronic airway conditions.2,10,11 Noncompliance 
with drug treatment continues to be a significant barrier to 
asthma control, which contributes to costly exacerbations and 
worsening of the disease over time.12 Medication compliance 
implies that the patient follows doctor’s orders and patient’s 
medication-taking behavior corresponds with doctor’s recom-
mendations with respect to timing, dosage, and frequency.13–15 
Over the past few years, researchers from several disciplines 
raised that poor compliance is an important problem for the 
national health care system around the world and should be 
treated from a multidisciplinary perspective.9,12,13
The aim of this study was to examine medication compli-
ance in asthmatic patients, focusing on the associations between 
compliance with asthma medication and inhaler devices such as 
dry powder inhaler (DPI) or pressurized metered-dose inhaler 
(pMDI). Moreover, some other confounders of compliance 
were analyzed, which were beyond clinical aspects.
Materials and methods
study sample
We conducted a retrospective and multicenter study based on 
review of medical registries of asthmatic patients treated with 
ICS/LABA combinations, whose medical devices were either 
DPIs (such as Accuhaler®, Turbuhaler®, or NEXThaler®) 
or pMDI. The study population included patients attending 
primary care centers, whose population was mostly urban, 
with a low-to-medium socioeconomic level.
The study sample was comprised of all asthmatic patients 
who started taking ICS/LABA delivered by a DPI or pMDI 
between 2007 and 2014. Moreover, patients needed to fulfill 
the following characteristics: 1) aged 18 and over; 2) time 
of diagnosis .3 years; 3) patients were required to have 
registries with regular monitoring for 18 months (ie, those 
who were part of the long-term prescription program to 
obtain drugs with a confirmed record of the daily dosage, 
time interval, and duration of each treatment). We excluded 
patients who were transferred outside the area and patients 
permanently institutionalized.
Data source
Patient compliance for each medication was tracked for 
1.5 years using persistence and adherence information. We 
obtained information on asthma treatment with ICS/LABA 
combination accordingly, with the Anatomical Therapeutic 
Chemical Classification System. Moreover, we linked each 
ICS/LABA combination to its medical device: Accuhaler®, 
Turbuhaler®, NEXThaler®, or pMDI. Data on diagnoses for 
a given individual were linked to medication associated with 
asthma using pharmacy administrative database and clinical 
visit data from electronic patient records. These databases are 
managed by Badalona Serveis Assitencials, which provides 
services to ten primary care centers, one hospital, and one 
socio-health center. Ethics approval for the database to be 
used for research was granted by the Hospital Germans Trías 
i Pujol Ethics Committee. No consent form from patients or 
caregivers was required for this study because data included 
in this database went through an anonymization process for 
patients’ information, guaranteed by the Badalona Serveis 
Assistencials S.A. organization that had access to the data.
Data on persistence of each patient at the 3rd, 6th, 12th, 
and 18th month were obtained (Figures 1 and 2) as well as 
information on medication possession, by patient’s refill 
count, and duration, by the number of days the patient should 
be consuming the medication. Other potential explanatory 
variables of compliance were considered after literature 
review and most of them were available in electronic patient 
reports. Number of exacerbations per patient during the 
study period was collected and more specifically data on 
number of mild/moderate exacerbations and acute events. 
These acute exacerbations implied hospitalizations patients 
could not control the exacerbation at home. We also gathered 
data on additional medication. However, we did not analyze 
compliance toward this medication since we were interested 
on compliance patterns in patients attempting to take ICS/
LABA fixed dose combinations chronically.
Clinical data on comorbidities were included.16 It was 
indicated whether the patient suffered simultaneous condition 
such as hypertension, diabetes, dyslipidemia, depression, and 
dementia. We also decided to indicate severe events including 
organ failures, ischemic heart disease, stroke, cerebrovascular 
disease, and neoplasm. Behavior attitudes that could result 
in higher risk of for instance obesity, smoking habit, and 
alcoholism were also included as comorbidities.17
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Moreover, we considered the number of visits in primary 
care centers for general practitioner (GP) consultation, 
hospital emergency visits, and we had access to pharmacy 
registries that gather the gross amount of pharmaceutical 
expenditure. Amounts were adapted into our model by 
obtaining patient’s average cost per month, and because 
Spanish patients have low co-payment levels, this proxy 
might be more accurate than the gross amount. Sick leave 
days were also gathered.18 Demographics of this sample were 
age, sex, and whether the patient was retired or not.19,20
calculation of patient’s medication 
compliance
To calculate compliance, we utilized the medication 
possession ratio (MPR), which is calculated by dividing 
the number of days supplied for a given medication by the 
number of days in the study, and persistence data.21 First, 
we identified persistent patients as those who used their 
medication for 18 months. These patients were analyzed 
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Figure 1 Percentage of persistent patients at the 3rd, 6th, 12th, and 18th month.
Abbreviations: DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler.
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Figure 2 Medication compliance.
Abbreviations: DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler.
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to obtain compliance by using the MPR. Therefore, within 
these persistent patients we applied a cut-point of 95% to 
the MPR, which tends to be overestimated,9,22 thus we also 
increased the limit to where patients were considered actively 
compliant. In the end, we had an ordered categorical variable, 
which showed to be very useful to identify persistence and 
compliance patterns, since patients first need to be persistent 
with their treatment and then they need to comply with their 
prescriptions.9,13 This variable reflects patients who are not 
either persistent or compliant, patients who are persistent but 
noncompliant, and patients who are persistent and showed 
compliance to their medication (Figure 3). Finally, to check 
the robustness of our findings, we decided to use the most 
common cut-point that is 80% to the MPR.14,23
Analysis
To describe the distribution of patient’s compliance within 
each medical device (DPI or pMDI), we tabulated sample 
characteristics for patients using either a DPI or a pMDI. 
Univariate associations between drug compliance, medical 
device, and several confounders such as age, comorbidities, 
exacerbations, severity of asthma, concomitant and rescue 
medication, and drug cost were analyzed.
In order to determine a specification that provides a better 
fit of the data for explaining compliance outcomes, interaction 
terms between the proxy of inhaler technique and the con-
founders of interest were also included. The impact of exac-
erbations relative to each inhaler device toward adherence 
was captured by computing the probability of having an 
exacerbation for each device of interest. The effect of severity 
of asthma for each type of DPIs was also examined.
With reference to health care utilization, visits to the 
GP were categorized in order to explore the association 
of having, on average: none or one visit per month, one to 
two visits per month, and more than three visits per month. 
Further, patients’ visits to their GP were computed per active 
substance. The effect of GP consultation for retired patients 
was also obtained. We considered a variable for comorbidity 
status, which was categorized as having 1, 2, 3, or more than 
4 conditions.
Additionally, having an acute event (ischemic heart 
disease, organ failures, stroke, or cerebrovascular diseases) 
was added into the regression. Moreover, to consider the 
potential heterogeneity sources across age groups, the continu-
ous variable age was split into seven groups. Finally, the effect 
of cost toward adherence for each age group was introduced in 
order to approximate the effect of socioeconomic status.20
Results
clinical and demographic characteristics
Characteristics of underlying populations of DPI users 
(73.2%) and pMDI users (26.8%) are presented in Table 1. 
Asthmatic patients (n=2,213) were predominantly female 
(61.46%), working-age (59.69%), and age distribution was 
very similar among the sample except for the oldest age 
group (5.60%) in which patients were 83–96 years old. Time 
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Figure 3 Percentage of patients’ compliance for each inhaler device (n=2,213).
Abbreviations: DPi, dry powder inhaler; pMDi, pressurized metered dose inhaler.
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since asthma was diagnosed (in years) was similar in both 
groups, however, its distribution varies widely and it goes 
from 3 years to 76.13 years. The most frequent comorbidity 
observed in this sample is dyslipidemia (37.7%), followed 
by obesity (27.9%), and diabetes (24.9%), which were very 
similar in both groups. Nearly half of the patients had moder-
ate persistent asthma. It was interesting to note that 79.35% 
of the sample did not experience any exacerbation event. 
Table 1 characteristics of cOPD patients according to type of inhaler device used
Characteristics pMDI
n=593 (26.8%)
DPI
n=1,620 (73.2%)
Total
N=2,213
P-value
Female, % 60.9% 61.7% 61.5% 0.735
Age mean (sD), years 52.3 (19.6) 53.2 (18.8) 52.9 (18.5) 0.326
18–28 15.85% 7.78% 9.94% nA
29–39 15.17% 18.14% 17.35% nA
40–50 14.84% 21.19% 20.02% nA
51–61 17.03% 19.19% 18.62% nA
62–72 17.53% 16.29% 16.63% nA
73–83 16.02% 10.31% 11.84% nA
83–96 3.54% 6.36% 5.60% nA
retirement status 40.5% 40.6% 40.6% 0.966
Time since diagnosis (sD), years 13.0 (5.3) 13.0 (4.2) 13.0 (4.5) 0.994
Asthma classification
Mild intermittent 19.7% 19.4% 19.5% nA
Mild persistent 31.0% 30.5% 30.6% nA
Moderate persistent 46.5% 47.3% 47.1% nA
severe persistent 2.7% 2.7% 2.7% 0.990
FeV1 (sD) 76.6 (9.9) 79.1 (9.9) 79.2 (9.9) 0.256
Allergy 43.84% 49.13% 47.72% 0.892
ics/lABA combination
Formoterol/beclomethasone 31.2% 14.4% 18.9% nA
Formoterol/budesonide 0.0% 60.6% 44.4% nA
Salmeterol/fluticasone 68.8% 25.0% 36.7% nA
exacerbations 14.7% 22.8% 20.7% ,0.001
Moderate 11.6% 22.0% 19.2% ,0.001
Acute 5.2% 6.7% 6.3% 0.199
comorbid conditions
Obesity 27.7% 28.0% 27.9% 0.650
smoking 21.8% 22.4% 22.2% 0.743
Alcoholism 2.7% 2.6% 2.6% 0.891
cardiovascular event 9.8% 9.7% 9.7% 0.948
hypertension 25.6% 24.7% 24.9% 0.650
Diabetes 14.3% 13.8% 13.9% 0.732
Dyslipidemia 38.8% 37.3% 37.7% 0.518
cerebrovascular events 7.4% 6.7% 6.9% 0.570
ischemic heart disease 4.4% 4.3% 4.3% 0.948
Organ failures 12.3% 12.3% 12.3% 0.987
Dementia 2.2% 2.2% 2.2% 0.964
Depression 18.5% 18.2% 18.3% 0.855
neoplasm 9.8% 9.5% 9.6% 0.846
Additional medication
Oral corticosteroids 14.7% 22.8% 20.7% ,0.001
systemic antibiotics 2.7% 7.0% 5.9% ,0.001
sABA 80.3% 80.4% 80.3% 0.958
number of visits to gP, (sD) 12.5 (11.3) 17.0 (14.0) 15.8 (13.5) ,0.001
Mean of number of visits to the emergency room, (sD) 0.1 (0.3) 0.2 (0.5) 0.2 (0.5) ,0.001
Mean of cost of pharmacological treatment (sD), euros 502.0 (510.4) 407.0 (407.8) 432.4 (439.5) ,0.001
Days off from work (sD) 2.5 (18.4) 3.2 (22.2) 3.1 (21.2) 0.444
Mean of total health care cost per patient (sD), euros 1,261 (2,093.8) 1,520 (2,562.9) 1,449.9 (2,448.4) 0.024
Note: Patients’ characteristics of those who visited their primary care center between January 2007 and June 2014.
Abbreviations: cOPD, chronic obstructive pulmonary disease; DPi, dry powder inhaler; FeV1, forced expiratory volume in the first second; GP, general practitioner; ICS/
lABA, inhaled corticosteroid and long-acting β2-agonist; nA, not applicable; pMDi, pressurized metered dose inhaler; sABA, short-acting β2-agonist; sD, standard deviation.
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Across clusters, DPI users had higher rate of exacerbations 
compared to pMDI users (P,0.001) and severe exacerba-
tions were more prevalent for DPI users (P,0.001).
Table 2 contains estimates of the univariate analysis 
and significance levels. At a first glance, having DPIs was 
negatively associated with compliance. Regarding active 
substances, patients taking salmeterol/fluticasone combina-
tion tend to have higher compliance compared to patients 
taking formoterol/beclomethasone combinations; in contrast 
the coefficient for the variable of salmeterol/fluticasone 
combination was not statistically significant. Most of the 
comorbidities were not statistically significant and only 
hypertension and organ failures correlated positively with 
compliance. Number of exacerbations and most specifically 
moderate exacerbations were positively correlated with better 
compliance outcomes. Mild, moderate, and severe persistent 
asthma were correlated with better compliance compared 
to intermittent asthma. Regarding utilization of health care 
Table 2 Univariate analysis of potential confounders of compliance
Category Compliance
Percentage points Odds ratio 95% CI
Explanatory variables
DPi compared to pMDi -5.89 0.706 (0.593–0.841)
ics/lABA (baseline formoterol/beclomethasone)
Formoterol/budesonide -0.37 0.976 (0.789–1.207)
Salmeterol/fluticasone 5.99** 1.409** (1.131–1.755)
Therapy line (baseline first line)
second line 17.47* 2.441* (1.848–3.224)
Third line 68.98* 31.384* (11.00–89.52)
FeV1 measure -0.41 0.97 (0.968–0.983)
Age 0.11** 1.007** (1.002–1.011)
Male 1.50 1.092 (0.932–1.281)
retired 4.17** 1.278** (1.090–1.498)
Obesity 1.73 1.108 (0.932–1.317)
smoking -4.15** 0.783** (0.648–0.945)
stroke 2.52 1.160 (0.839–1.602)
cerebrovascular disease 3.23 1.210 (0.923–1.584)
hypertension 3.64* 1.239* (1.035–1.484)
Diabetes -2.53 0.861 (0.685–1.082)
Dyslipidemia -0.57 0.994 (0.847–1.167)
Alcoholism 6.18 1.439 (0.905–2.290)
ischemic heart disease 2.77 1.177 (0.801–1.731)
Organ failures 6.29** 1.449** (1.139–1.843)
Dementia -4.29 0.777 (0.450–1.341)
Depression -1.75 0.902 (0.737–1.035)
neoplasm 0.36 1.021 (0.781–1.335)
Allergy 3.84** 1.255** (1.074–1.465)
number of exacerbations 2.01** 1.126** (1.018–1.245)
number of acute exacerbations 0.76 1.046 (0.761–1.438)
number of mild/moderate exacerbations 2.77** 1.178** (1.047–1.325)
severity of asthma (baseline intermittent)
Mild persistent 8.40* 1.857* (1.480–2.327)
Moderate persistent 13.52* 2.473* (2.000–3.057)
severe persistent 17.85* 3.064* (1.865–5.032)
Time from diagnosis 0.26 1.01 (0.999–1.033)
Oral corticosteroids 2.91 1.187 (0.982–1.435)
systemic antibiotics 8.40** 1.642** (1.187–2.274)
sABA 6.96* 1.509* (1.240–1.836)
Visits to gP 0.21* 1.012* (1.006–1.018)
emergency visits 2.05 1.12 (0.962–1.323)
sick leave -0.04 0.99 (0.993–1.001)
cost -0.11* 0.994* (0.991–0.996)
Notes: *P,0.001, **P,0.05.
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; FEV1, forced expiratory volume in the first second; GP, general practitioner; ICS/LABA, inhaled 
corticosteroid and long-acting β2-agonist; pMDi, pressurized metered dose inhaler; sABA, short-acting β2-agonist; sD, standard deviation.
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resources, an extra visit to the GP was positively linked to 
compliance, while cost was negatively correlated with it. 
Patient characteristics such as age, retirement status, and 
allergy were positively correlated with compliance.
inhaler technique and other confounders 
affecting patient’s compliance to the 
asthma treatment
The patterns of the relationship from the multivariate ordered 
logistic regression model matched some of those of the uni-
variate results (Table 3). Indeed, the probability of having 
more negative compliance is larger for DPI users compared 
to patients using pMDI. These patterns also fit for severity 
of asthma, allergy, acute exacerbations, and cost. In contrast, 
age, comorbidities, moderate exacerbations, and retirement 
were not statistically correlated with compliance. After 
controlling for the ICS/LABA combination, which became 
statistically significant, the magnitude of DPIs’ effect on com-
pliance in comparison with pMDI outcomes decreased.
The final specification showed to fit the data better for 
explaining compliance patterns (Table 4). Having a DPI 
would decrease the probability of asthmatic patients to 
comply with their treatment compared to pMDI. Moreover, 
deterioration of forced expiratory volume in the first second 
measure by 1 unit and having $3 comorbidities would 
decrease the probability of medication compliance. More 
than one doctor’s consultation per month was associated with 
worse adherence. Patients who belonged to 29–39, 40–50, 
and 51–61 age groups were more likely to be adherent com-
pared to the oldest group, as well as those who suffered more 
than two moderate exacerbations compared to those who did 
not experience any exacerbation. An additional doctor visit 
was associated with better adherence. Alcoholism, which 
was the only comorbidity statistically significant, was posi-
tively associated with compliance. Again, active substance 
categorical variable was not statistically significant.
The introduction of interaction terms revealed interest-
ing results. The effect of exacerbations varies across inhaler 
devices and the probability of being a compliant patient 
with Accuhaler® who suffered an exacerbation is lower 
compared to the rest of DPI users. However, as asthma gets 
worse, Accuhaler® devices have a small but positive effect 
toward compliance compared to the pMDI. Estimates of the 
other DPIs were not statistically significant. In the case of 
healthcare utilization, the patient’s probability of medication 
compliance would be lower for those who visited their GP 
Table 3 Multivariate results of potential confounders of compliance
McFadden’s R2=0.029 Compliance
Without active substance Controlling for active substances
Percentage points Odds ratio 95% CI Percentage points Odds ratio 95% CI
Explanatory variables
Medical device DPi -6.46* 0.69* (0.575–0.841) -4.48** 0.77** (0.617–0.972)
ics/lABA
Formoterol/budesonide – – – 1.02 1.065 (0.830–1.368)
Salmeterol/fluticasone – – – 5.78** 1.398** (1.104–1.770)
severity
Persistent mild 11.02* 2.22* (1.737–2.834) 10.81* 2.188* (1.712–2.796)
Persistent moderate 15.42* 2.82* (2.203–3.610) 15.26* 2.791* (2.180–3.575)
Persistent severe 24.08* 4.26* (1.994–9.124) 24.41* 4.322* (2.017–9.260)
Therapy line
second 14.04* 2.10* (1.558–2.831) 13.69* 2.07* (1.535–2.791)
Third 65.53* 29.0* (9.794–85.92) 65.20* 28.43* (9.575–84.45)
Age 0.13 1.008 (0.999–1.016) 0.12 1.007 (0.999–1.015)
retired 2.96 1.188 (0.843–1.597) 2.97 1.190 (0.885–1.601)
smoker -1.74 0.902 (0.733–1.109) -1.87 0.894 (0.727–1.100)
hypertension -0.95 0.946 (0.748–1.194) -0.95 0.945 (0.748–1.194)
Organ failures 3.06 1.195 (0.896–1.595) 2.93 1.187 (0.889–1.585)
Allergy 3.70** 1.24** (1.045–1.474) 3.96** 1.261** (1.061–1.497)
Acute exacerbations -8.02* 0.626* (0.417–0.938) -8.61** 0.604** (0.402–0.907)
Mild/moderate exacerbations 0.67 1.040 (0.868–1.245) 0.746 1.04 (0.871–1.252)
Pharmacological cost -0.170* 0.988* (0.986–0.992) -0.179* 0.989* (0.986–0.992)
Visit to gP 0.04 1.002 (0.995–1.009) 0.04* 1.002* (0.995–1.009)
Notes: *P,0.001, **P,0.05.
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; GP, general practitioner; ICS/LABA, inhaled corticosteroid and long-acting β2-agonist; pMDi, pressurized 
metered dose inhaler; –, not considered within the regression.
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Table 4 Final specification: ordered logistic regression analysis: predicting compliance for asthmatic patients
McFadden’s R2=0.239 Compliance
Percentage points Odds ratio 95% CI
Explanatory variables
DPi compared to pMDi -10.67** 0.457** (0.229–0.909)
ics/lABA compared to formoterol/beclomethasone
Formoterol/budesonide 7.75 1.761 (0.837–3.706)
Salmeterol/fluticasone 3.37 1.309
FeV1 9.78* 0.977* (0.959–0.996)
Therapy line
second line 0.75 1.056 (0.755–1.475)
Third line 52.7* 27.09* (8.657–84.78)
Age groups compared to the oldest group
18–28 6.25 2.236 (0.841–6.427)
29–39 15.64** 3.625** (1.375–9.547)
40–50 12.68** 2.961** (1.150–7.634)
51–61 13.59** 3.154** (1.368–7.727)
62–72 -4.59 1.496 (1.496–3.141)
73–83 -9.38 1.598 (0.738–3.460)
retirement 1.71 1.342 (0.540–2.379)
Allergy 1.76 1.138 (0.937–1.381)
number of comorbidities 
1 -1.86 0.877 (0.665–1.157)
2 -4.82 0.704 (0.488–1.017)
3 -7.52** 0.566** (0.367–0.874)
.4 -7.16** 0.584** (0.505–1.557)
Acute event/condition 1.08 1.082 (0.796–1.471)
Obesity 2.69 1.218 (0.933–1.591)
Alcoholism 7.98** 1.795** (1.013–3.179)
smoking 0.58 1.043 (0.788–1.381)
Acute exacerbation -1.60 0.886 (0.505–1.557)
Moderate (compared with no exacerbation)
1 moderate exacerbation 15.03 2.736 (1.003–6.463)
$2 moderate exacerbations 20.35** 3.726** (1.111–10.49)
Visit to the emergency room -8.20 0.517 (0.235–1.134)
Additional visit to the gP 1.98* 1.156* (1.137–1.175)
Visiting a gP
Two times per month (on average) -25.83* 0.094* (0.674–0.131)
Three times per month (on average) -39.12* 0.025* (0.001–0.005)
Average pharmacological cost per month 0.22 1.016 (0.998–1.035)
Day lost due to some event related with asthma -0.81 0.941 (0.680–1.300)
Potential underlying mechanism
severity related to DPi
severity/Accuhaler® 4.98** 1.441** (1.049–1.978)
severity/Turbuhaler® 4.98 1.037 (0.812–1.324)
severity/neXThaler® 2.64 1.214 (0.877–1.680)
exacerbations related to each inhaler
Accuhaler® -21.98* 0.199* (0.074–0.532)
Turbuhaler® -9.84 0.482 (0.193–1.203)
neXThaler® -15.25** 0.326** (0.107–0.995)
pMDi -14.24** 0.351** (0.139–0.886)
Visit to gP related to each ics/lABA 
Salmeterol/fluticasone -65.84* 0.008* (0.001–0.498)
Formoterol/budesonide -90.17* 0.0013* (0.001–0.009)
Formoterol/fluticasone -65.43* 0.008* (0.001–0.055)
Visit to gP for retired patient 4.15** 1.356** (0.992–0.055)
costs for each age group (baseline 83–97 group)
18–28 -0.37** 0.973** (0.948–0.998)
(Continued)
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more than 3 times and were treated with Formoterol/Budes-
onide combination compared to patients taking the other ICS/
LABA combinations, although the common effect of visit-
ing their GP was observed to be a positive association with 
compliance (see previous paragraph). The effect of GP visits 
toward compliance was greater for retired patients compared 
to working-age patients and retired ones who did not visit 
the GP during the study period. The negative effect of cost 
through age affected mostly younger patients and became 
not statistically significant for older age groups.
Robustness check confirmed our results, which implied 
that inhaler technique associated with DPIs would decrease 
the probability of patients to adhere to asthma medication 
(P,0.001).
Discussion
Our study shows that the inhaler technique associated with 
inhaler devices can affect compliance of asthmatic patients. 
In fact, findings are consistent with previous literature that 
shows patient’s compliance as a real and latent problem 
within chronic conditions.12 In our case, we explored the 
problem of compliance toward asthma medication while 
controlling for potential confounders. We controlled for the 
effect of active substance toward the probability to stick to 
the treatment,24 so we could obtain the potential effect of 
the inhaler device. Interestingly, findings suggest that ICS/
LABA combinations would not impact on the probability 
of being adherent, which is reasonable since medicines are 
100% effective but the inhalation technique is the key for 
better clinical outcomes.1–3,7
Along with inhaler technique, different confounders 
of patient’s compliance were explored. Univariate results 
determined that only a few variables were associated with 
medication compliance. The proxy for inhaler technique was 
statistically significant; in contrast, patients’ characteristics, 
comorbidities, and health outcomes that were significant in 
the univariate analysis became nonstatistically significant 
in the basic multivariate specification. However, in our last 
specification we identified confounders of compliance from 
the interaction between variables. This indicates that a basic 
analysis was not enough to identify factors affecting compli-
ance outcomes, and as it has been reported, adherence and 
compliance are a more complex topic.25 According to our 
results, having more than three conditions simultaneously 
would impact negatively on the likelihood of medication 
compliance. Suffering from a disease is a burden for patients, 
and it is reported that there is a substantial burden on patients 
having more than three simultaneous conditions, which starts 
to affect their compliance to asthma treatment (as we have 
observed in our results), and may require more complex 
health management strategies.26,27 Remarkably, unhealthy 
behaviors of patients were not statistically significant in 
compliance. However, we identified a scope for improve-
ment since we detected that 22% of the sample were smokers 
despite their asthmatic condition.
Despite the positive effect of GP consultation for com-
pliance, a high number of visits per month to health care 
professionals was negatively correlated with it. Indeed, 
greater number of visits was associated with worse compli-
ance outcomes, which is consistent with previous literature 
that reported reductions in health care utilization due to 
good compliance with asthma treatment.28 Further, the 
effect of visits for retired patients is positive for compliance 
compared to active patients and retired patients who did not 
visit their GP during the time they were persistent with their 
medication. This is consistent with previous findings that 
suggest for elderly, GP consultation should be encouraged 
in order to maintain patient’s compliance to medication in 
the long term.29
Accordingly with our results, younger age groups were 
more likely to be compliant patients.19 However, this effect 
might be offset due to the effect of costs toward compli-
ance. Our results for the interaction between age and cost 
suggest pharmacological cost for younger groups would 
decrease the probability of being compliant. It may be that 
the effect of bearing some part of the pharmaceutical cost 
Table 4 (Continued)
McFadden’s R2=0.239 Compliance
Percentage points Odds ratio 95% CI
29–39 -0.29** 0.978** (0.958–0.998)
40–50 -0.22 0.983 (0.964–1.003)
51–61 0.29** 0.978** (0.962–0.994)
62–72 0.007 1.005 (0.987–1.015)
73–83 0.003 1.002 (0.987–1.010)
Notes: *P,0.001, **P,0.05.
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; FEV1, forced expiratory volume in the first second; GP, general practitioner; ICS/LABA, inhaled 
corticosteroid and long-acting β2-agonist; pMDi, pressurized metered dose inhaler; sD, standard deviation; –, not considered within the regression.
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for patients whose salary was not very high represented 
an economic burden that influences compliance to a treat-
ment. In contrast, cost for older groups was not statisti-
cally significant; this is reasonable since elderly Spanish 
patients have access to pharmaceutical treatment without 
co-payments.30
There are limitations to these estimates besides the fact 
that this is a retrospective study, which is vulnerable to bias. 
First, this study was conducted in a single health system, 
thus results may not be extrapolated to other populations. 
However, trends are similar to previous research.22,23,25 
Second, the assumption that obtaining a prescription was 
equivalent to taking the medication might not be completely 
accurate. Moreover, the study approach to quantify compli-
ance was done by using the MPR, which has been reported 
to be biased upwards.9,14 Nevertheless, we tried to correct 
for this by elevating the cut-off point so fewer patients were 
seen as compliant with their medication. Robustness test of 
estimates confirmed our findings. Actually, our estimates 
could be considered accurate, since we used persistence to 
asthma treatment data. It is also true that tracking compli-
ance patterns may imply having data across time; how-
ever, this could be only possible by assessing compliance 
prospectively.
It is worth mentioning that physicians have been aware 
that the majority of patients cannot use their prescribed 
pMDI correctly;31 and DPIs included in this study were 
seen as an effective alternative to solve problems related to 
inhaler technique. However, our results suggest that there 
is still a crucial barrier to avoid the loss of pharmacological 
efficacy due to the inhaler technique associated with DPIs 
included in this analysis, which determines compliance of 
long-term medication in asthmatic patients. Finally, we could 
not obtain some patients’ characteristics such as race, level 
of education, type of job, and some clinical confounders 
such as lung function. This problem of data limitation also 
restricts our outcomes.
Conclusion
The effect of inhaler technique associated with DPIs included 
in this anaylsis (Accuhaler®, nexThaler®, and Turubhlaer) 
was negative towards compliance for long-term asthma 
medication. In contrast, the active substance was not sig-
nificant in exploring compliance patterns. Furthermore, we 
identified some other confounders of patient’s compliance 
such as severity of asthma, comorbidities, cost, age, and 
health care utilization. Associations between exacerbations 
and patient’s compliance have shown to be divergent across 
inhaler devices.
Treatment noncompliance is a real and damaging prob-
lem for patients and for the Spanish National Healthcare 
System. The quantification of compliance and persistence is 
always an issue in current literature, which can limit results; 
identification of potential factors affecting compliance is 
necessary in order to guide actions to attenuate the problem 
of poor compliance in asthma patients. This study assess-
ing treatment compliance across asthma inhaler devices for 
ICS/LABA combinations confirms that inhaler devices play 
an important role in asthma management by conditioning 
compliance, which is consistent with prior research.1–9,17,23 
The special feature of our findings is that we adjusted for the 
effects of the active substances in order to explore the effect 
of inhaler technique toward compliance, which has shown to 
be influenced also by patients’ demographic characteristics 
and clinical aspects. Helping patients to properly use their 
inhaler devices, has shown to be the key for better compliance 
outcomes, as we observed that inhaler technique might be 
diminishing the efficacy of pharmacological treatment.
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